

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**761028Orig1s000**

**PROPRIETARY NAME REVIEW(S)**

---

**PROPRIETARY NAME REVIEW**

Division of Medication Error Prevention and Analysis (DMEPA)  
Office of Medication Error Prevention and Risk Management (OMEPRM)  
Office of Surveillance and Epidemiology (OSE)  
Center for Drug Evaluation and Research (CDER)

**\*\*\* This document contains proprietary information that cannot be released to the public\*\*\***

---

<b>Date of This Review:</b>	February 8, 2017
<b>Application Type and Number:</b>	BLA 761028
<b>Product Name and Strength:</b>	Mvasi (bevacizumab-____) <sup>a</sup> Injection, 25 mg/mL
<b>Total Product Strength:</b>	100 mg/4 mL and 400 mg/16 mL
<b>Product Type:</b>	Single Ingredient Product
<b>Rx or OTC:</b>	Rx
<b>Applicant/Sponsor Name:</b>	Amgen
<b>Panorama #:</b>	2016-11505301
<b>DMEPA Primary Reviewer:</b>	Janine Stewart, PharmD
<b>DMEPA Team Leader:</b>	Chi-Ming (Alice) Tu, PharmD, BCPS

---

---

<sup>a</sup> Mvasi has been developed as a proposed biosimilar to US-licensed Avastin (bevacizumab). Since the proper name for Mvasi has not yet been determined, “bevacizumab-\_\_\_\_” is used throughout this review as the proper name for this product.

## Contents

1	INTRODUCTION.....	3
1.1	Product Information.....	3
2	RESULTS.....	4
2.1	Misbranding Assessment.....	4
2.2	Safety Assessment.....	4
3	CONCLUSIONS.....	5
3.1	Comments to the Applicant.....	6
4	REFERENCES.....	7
	APPENDICES.....	8

## 1 INTRODUCTION

This review evaluates the proposed proprietary name, Mvasi, from a safety and misbranding perspective. The sources and methods used to evaluate the proposed name are outlined in the reference section and Appendix A respectively. The Applicant submitted an external name study, conducted by [REDACTED] <sup>(b) (4)</sup> for this product.

### 1.1 PRODUCT INFORMATION

The following product information is provided in the November 14, 2016 proprietary name submission.

- Intended Pronunciation: em vah' see
- Active Ingredient: bevacizumab-\_\_\_\_\_
- Indication of Use: Treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic carcinoma of the cervix.
- Route of Administration: Intravenous
- Dosage Form: Injection
- Strength: 100 mg/4 mL and 400 mg/16 mL (25 mg/mL)
- Dose and Frequency:
  - Metastatic colorectal cancer-
    - 5 mg/kg intravenously every 2 weeks with bolus-IFL
    - 10 mg/kg intravenously every 2 weeks with FOLFOX4
    - 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy after progression on a first-line [bevacizumab-\_\_\_\_\_] containing regimen
  - Non-squamous non-small cell lung cancer-
    - 15 mg/kg intravenously every 3 weeks with carboplatin/paclitaxel
  - Glioblastoma-
    - 10 mg/kg intravenously every 2 weeks
  - Metastatic renal cell carcinoma (mRCC)-
    - 10 mg/kg intravenously every 2 weeks with interferon alfa
  - Persistent, recurrent, or metastatic carcinoma of the cervix-
    - 15 mg/kg intravenously every 3 weeks with paclitaxel/cisplatin or paclitaxel/topotecan
- How Supplied: single-dose vials
- Storage: Refrigerate at 2–8°C (36–46°F). Vials should be protected from light. Do not freeze or shake

## **2 RESULTS**

The following sections provide information obtained and considered in the overall evaluation of the proposed proprietary name.

### **2.1 MISBRANDING ASSESSMENT**

The Office of Prescription Drug Promotion (OPDP) determined that the proposed name would not misbrand the proposed product. DMEPA and the Division of Oncology Products 2 (DOP2) concurred with the findings of OPDP's assessment of the proposed name.

### **2.2 SAFETY ASSESSMENT**

The following aspects were considered in the safety evaluation of the name.

#### ***2.2.1 United States Adopted Names (USAN) Search***

There is no USAN stem present in the proprietary name<sup>b</sup>.

#### ***2.2.2 Components of the Proposed Proprietary Name***

The Applicant did not provide a derivation or intended meaning for the proposed name, Mvasi in their submission. This proprietary name is comprised of a single that does not contain any components (i.e. a modifier, route of administration, dosage form, etc.) that are misleading or can contribute to medication error.

#### ***2.2.3 FDA Name Simulation Studies***

Ninety-eight practitioners participated in DMEPA's prescription studies. The responses did not overlap with any currently marketed products nor did the responses sound or look similar to any currently marketed products or any products in the pipeline. Common misinterpretations of the verbal study included the "M" being interpreted as "Am", "Em" or "Hem". Appendix B contains the results from the verbal and written prescription studies.

#### ***2.2.4 Comments from Other Review Disciplines at Initial Review***

In response to the OSE, December 1, 2016 e-mail, the Division of Oncology Products 2 (DOP2) forwarded a comment relating to the proposed proprietary name at the initial phase of the review. One review team member expressed the following:

"When I read this name the very first thing that came to mind was ads for Multiple Vascular Indications."

DMEPA asked OPDP to re-assess the name, Mvasi, based on the comment from the review team via email on February 1, 2017. After considering the comment, OPDP replied via email on February 3, 2017 and maintained their non-objection to the name, Mvasi, from a promotional perspective.

---

<sup>b</sup> USAN stem search conducted on December 23, 2016.

Based on OPDP’s input and past input from the FDA Office of the Chief Counsel (OCC) regarding objecting to a proposed proprietary name based on promotional, misleading or misbranding aspects, DMEPA agreed with OPDP’s determination that we lack the basis to find this name unacceptable for misbranding reasons. We informed DOP2 of our misbranding evaluation via email on February 7, 2017, and offered to meet with DOP2 if further discussion is warranted. DOP2 aligned with our misbranding evaluation and did not request to meet.

**2.2.5 Phonetic and Orthographic Computer Analysis (POCA) Search Results**

Table 1 lists the number of names with the combined orthographic and phonetic score of  $\geq 55\%$  retrieved from our POCA search<sup>c</sup> and also includes names identified by (b) (4). These names are organized as highly similar, moderately similar or low similarity for further evaluation.

<b>Table 1. Similarity Category</b>	<b>Number of Names</b>
Highly similar name pair: combined match percentage score $\geq 70\%$	1
Moderately similar name pair: combined match percentage score $\geq 55\%$ to $\leq 69\%$	23
Low similarity name pair: combined match percentage score $\leq 54\%$	10

**2.2.6 Safety Analysis of Names with Potential Orthographic, Spelling, and Phonetic Similarities**

Our analysis of the 34 names contained in Table 1 determined 34 names will not pose a risk for confusion as described in Appendices C through H.

**2.2.7 Communication of DMEPA’s Analysis at Midpoint of Review**

DMEPA communicated our findings to the Division of Oncology Products 2 (DOP2) via e-mail on February 1, 2017. At that time we also requested additional information or concerns that could inform our review. Per e-mail correspondence from the DOP2 on February 8, 2017, they stated no additional concerns with the proposed proprietary name, Mvasi.

**3 CONCLUSIONS**

The proposed proprietary name is acceptable.

If you have any questions or need clarifications, please contact Latonia Ford, OSE project manager, at 301-796-4910.

---

<sup>c</sup> POCA search conducted on January 3, 2016 in version 4.0.

### **3.1 COMMENTS TO THE APPLICANT**

We have completed our review of the proposed proprietary name, Mvasi, and have concluded that this name is acceptable.

If any of the proposed product characteristics as stated in your November 14, 2016 submission are altered prior to approval of the marketing application, the name must be resubmitted for review.

## 4 REFERENCES

1. ***USAN Stems*** (<http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council/naming-guidelines/approved-stems.page>)

USAN Stems List contains all the recognized USAN stems.

### ***2. Phonetic and Orthographic Computer Analysis (POCA)***

POCA is a system that FDA designed. As part of the name similarity assessment, POCA is used to evaluate proposed names via a phonetic and orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists that operates in a similar fashion. POCA is publicly accessible.

### ***Drugs@FDA***

Drugs@FDA is an FDA Web site that contains most of the drug products approved in the United States since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA-approved *brand name* and *generic drugs*; *therapeutic biological products*, *prescription* and *over-the-counter* human drugs; and *discontinued drugs* (see Drugs @ FDA Glossary of Terms, available at [http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm#ther\\_biological](http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm#ther_biological)).

### ***RxNorm***

RxNorm contains the names of prescription and many OTC drugs available in the United States. RxNorm includes generic and branded:

- Clinical drugs – pharmaceutical products given to (or taken by) a patient with therapeutic or diagnostic intent
- Drug packs – packs that contain multiple drugs, or drugs designed to be administered in a specified sequence

Radiopharmaceuticals, contrast media, food, dietary supplements, and medical devices, such as bandages and crutches, are all out of scope for RxNorm (<http://www.nlm.nih.gov/research/umls/rxnorm/overview.html#>).

### ***Division of Medication Errors Prevention and Analysis proprietary name consultation requests***

This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis from the Access database/tracking system.

### ***3. Electronic Drug Registration and Listing System (eDRLS) database***

The electronic Drug Registration and Listing System (eDRLS) was established to support the FDA's Center for Drug Evaluation and Research (CDER) goal to establish a common Structured Product Labeling (SPL) repository for all facilities that manufacture regulated drugs. The system is a reliable, up-to-date inventory of FDA-regulated, drugs and establishments that produce drugs and their associated information.

## APPENDICES

### Appendix A

FDA's Proprietary Name Risk Assessment evaluates proposed proprietary names for misbranding and safety concerns.

1. **Misbranding Assessment:** For prescription drug products, OPDP assesses the name for misbranding concerns. . For over-the-counter (OTC) drug products, the misbranding assessment of the proposed name is conducted by DNDP. OPDP or DNDP evaluates proposed proprietary names to determine if the name is false or misleading, such as by making misrepresentations with respect to safety or efficacy. For example, a fanciful proprietary name may misbrand a product by suggesting that it has some unique effectiveness or composition when it does not (21 CFR 201.10(c)(3)). OPDP or DNDP provides their opinion to DMEPA for consideration in the overall acceptability of the proposed proprietary name.
2. **Safety Assessment:** The safety assessment is conducted by DMEPA, and includes the following:
  - a. **Preliminary Assessment:** We consider inclusion of USAN stems or other characteristics that when incorporated into a proprietary name may cause or contribute to medication errors (i.e., dosing interval, dosage form/route of administration, medical or product name abbreviations, names that include or suggest the composition of the drug product, etc.) See prescreening checklist below in Table 2\*. DMEPA defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer.<sup>d</sup>

---

<sup>d</sup> National Coordinating Council for Medication Error Reporting and Prevention.  
<http://www.nccmerp.org/aboutMedErrors.html>. Last accessed 10/11/2007.

**\*Table 2- Prescreening Checklist for Proposed Proprietary Name**

	Answer the questions in the checklist below. Affirmative answers to any of these questions indicate a potential area of concern that should be carefully evaluated as described in this guidance.
<b>Y/N</b>	<b>Is the proposed name obviously similar in spelling and pronunciation to other names?</b>
	Proprietary names should not be similar in spelling or pronunciation to proprietary names, established names, or ingredients of other products.
<b>Y/N</b>	<b>Are there medical and/or coined abbreviations in the proprietary name?</b>
	Proprietary names should not incorporate medical abbreviations (e.g., QD, BID, or others commonly used for prescription communication) or coined abbreviations that have no established meaning.
<b>Y/N</b>	<b>Are there inert or inactive ingredients referenced in the proprietary name?</b>
	Proprietary names should not incorporate any reference to an inert or inactive ingredient in a way that might create an impression that the ingredient's value is greater than its true functional role in the formulation (21 CFR 201.10(c)(4)).
<b>Y/N</b>	<b>Does the proprietary name include combinations of active ingredients?</b>
	Proprietary names of fixed combination drug products should not include or suggest the name of one or more, but not all, of its active ingredients (see 21 CFR 201.6(b)).
<b>Y/N</b>	<b>Is there a United States Adopted Name (USAN) stem in the proprietary name?</b>
	Proprietary names should not incorporate a USAN stem in the position that USAN designates for the stem.
<b>Y/N</b>	<b>Is this proprietary name used for another product that does not share at least one common active ingredient?</b>
	Drug products that do not contain at least one common active ingredient should not use the same (root) proprietary name.
<b>Y/N</b>	<b>Is this a proprietary name of a discontinued product?</b>
	Proprietary names should not use the proprietary name of a discontinued product if that discontinued drug product does not contain the same active ingredients.

- b. Phonetic and Orthographic Computer Analysis (POCA): Following the preliminary screening of the proposed proprietary name, DMEPA staff evaluates the proposed name against potentially similar names. In order to identify names with potential similarity to the proposed proprietary name, DMEPA enters the proposed proprietary name in POCA and queries the name against the following drug reference databases, Drugs@fda, CernerRxNorm, and names in the review pipeline using a 50% threshold in POCA. DMEPA reviews the combined orthographic and phonetic matches and group the names into one of the following three categories:
- Highly similar pair: combined match percentage score  $\geq 70\%$ .
  - Moderately similar pair: combined match percentage score  $\geq 55\%$  to  $\leq 69\%$ .
  - Low similarity: combined match percentage score  $\leq 54\%$ .

Using the criteria outlined in the check list (Table 3-5) that corresponds to each of the three categories (highly similar pair, moderately similar pair, and low similarity), DMEPA evaluates the name pairs to determine the acceptability or non-acceptability of a proposed proprietary name. The intent of these checklists is to increase the transparency and predictability of the safety determination of whether a proposed name is vulnerable to confusion from a look-alike or sound-alike perspective. Each bullet below corresponds to the name similarity category cross-references the respective table that addresses criteria that DMEPA uses to determine whether a name presents a safety concern from a look-alike or sound-alike perspective.

- For highly similar names, differences in product characteristics often cannot mitigate the risk of a medication error, including product differences such as strength and dose. Thus, proposed proprietary names that have a combined score of  $\geq 70$  percent are at risk for a look-alike sound-alike confusion which is an area of concern (See Table 3).
- Moderately similar names with overlapping or similar strengths or doses represent an area for concern for FDA. The dosage and strength information is often located in close proximity to the drug name itself on prescriptions and medication orders, and it can be an important factor that either increases or decreases the potential for confusion between similarly named drug pairs. The ability of other product characteristics to mitigate confusion (e.g., route, frequency, dosage form, etc.) may be limited when the strength or dose overlaps. We review such names further, to determine whether sufficient differences exist to prevent confusion. (See Table 4).
- Names with low similarity that have no overlap or similarity in strength and dose are generally acceptable (See Table 5) unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

- c. FDA Prescription Simulation Studies: DMEPA staff also conducts a prescription simulation studies using FDA health care professionals.

Three separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of the proposed proprietary name with marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions or verbal pronunciation of the drug name. The studies employ healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The primary Safety Evaluator uses the results to identify orthographic or phonetic vulnerability of the proposed name to be misinterpreted by healthcare practitioners.

In order to evaluate the potential for misinterpretation of the proposed proprietary name in handwriting and verbal communication of the name, inpatient medication orders and/or outpatient prescriptions are written, each consisting of a combination of marketed and unapproved drug products, including the proposed name. These orders are optically scanned and one prescription is delivered to a random sample of participating health professionals via e-mail. In addition, a verbal prescription is recorded on voice mail. The voice mail messages are then sent to a random sample of the participating health professionals for their interpretations and review. After receiving either the written or verbal prescription orders, the participants record their interpretations of the orders which are recorded electronically.

- d. Comments from Other Review Disciplines: DMEPA requests the Office of New Drugs (OND) and/or Office of Generic Drugs (OGD), ONDQA or OBP for their comments or concerns with the proposed proprietary name, ask for any clinical issues that may impact the DMEPA review during the initial phase of the name review. Additionally, when applicable, at the same time DMEPA requests concurrence/non-concurrence with OPDP's decision on the name. The primary Safety Evaluator addresses any comments or concerns in the safety evaluator's assessment.

The OND/OGD Regulatory Division is contacted a second time following our analysis of the proposed proprietary name. At this point, DMEPA conveys their decision to accept or reject the name. The OND or OGD Regulatory Division is requested to provide any further information that might inform DMEPA's final decision on the proposed name.

Additionally, other review disciplines opinions such as ONDQA or OBP may be considered depending on the proposed proprietary name.

When provided, DMEPA considers external proprietary name studies conducted by or for the Applicant/Sponsor and incorporates the findings of these studies into the overall risk assessment.

The DMEPA primary reviewer assigned to evaluate the proposed proprietary name is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name.

**Table 3. Highly Similar Name Pair Checklist (i.e., combined Orthographic and Phonetic score is  $\geq 70\%$ ).**

<u>Orthographic Checklist</u>		<u>Phonetic Checklist</u>	
<b>Y/N</b>	Do the names begin with different first letters? <i>Note that even when names begin with different first letters, certain letters may be confused with each other when scripted.</i>	<b>Y/N</b>	Do the names have different number of syllables?
<b>Y/N</b>	Are the lengths of the names dissimilar* when scripted?  <i>*FDA considers the length of names different if the names differ by two or more letters.</i>	<b>Y/N</b>	Do the names have different syllabic stresses?
<b>Y/N</b>	Considering variations in scripting of some letters (such as <i>z</i> and <i>f</i> ), is there a different number or placement of upstroke/downstroke letters present in the names?	<b>Y/N</b>	Do the syllables have different phonologic processes, such as vowel reduction, assimilation, or deletion?
<b>Y/N</b>	Is there different number or placement of cross-stroke or dotted letters present in the names?	<b>Y/N</b>	Across a range of dialects, are the names consistently pronounced differently?
<b>Y/N</b>	Do the infixes of the name appear dissimilar when scripted?		
<b>Y/N</b>	Do the suffixes of the names appear dissimilar when scripted?		

**Table 4: Moderately Similar Name Pair Checklist (i.e., combined score is  $\geq 55\%$  to  $\leq 69\%$ ).**

<p>Step 1</p>	<p>Review the DOSAGE AND ADMINISTRATION and HOW SUPPLIED/STORAGE AND HANDLING sections of the prescribing information (or for OTC drugs refer to the Drug Facts label) to determine if strengths and doses of the name pair overlap or are very similar. Different strengths and doses for products whose names are moderately similar may decrease the risk of confusion between the moderately similar name pairs. Name pairs that have overlapping or similar strengths or doses have a higher potential for confusion and should be evaluated further (see Step 2). Because the strength or dose could be used to express an order or prescription for a particular drug product, overlap in one or both of these components would be reason for further evaluation.</p> <p>For single strength products, also consider circumstances where the strength may not be expressed.</p> <p>For any i.e. drug products comprised of more than one active ingredient, consider whether the strength or dose may be expressed using only one of the components.</p> <p>To determine whether the strengths or doses are similar to your proposed product, consider the following list of factors that may increase confusion:</p> <ul style="list-style-type: none"> <li>• Alternative expressions of dose: 5 mL may be listed in the prescribing information, but the dose may be expressed in metric weight (e.g., 500 mg) or in non-metric units (e.g., 1 tsp, 1 tablet/capsule). Similarly, a strength or dose of 1000 mg may be expressed, in practice, as 1 g, or vice versa.</li> <li>• Trailing or deleting zeros: 10 mg is similar in appearance to 100 mg which may potentiate confusion between a name pair with moderate similarity.</li> <li>• Similar sounding doses: 15 mg is similar in sound to 50 mg</li> </ul>
<p>Step 2</p>	<p>Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may reduce the likelihood of confusion for moderately similar names <b>with</b> overlapping or similar strengths or doses.</p>



	<p>Orthographic Checklist (Y/N to each question)</p> <ul style="list-style-type: none"> <li>• Do the names begin with different first letters? Note that even when names begin with different first letters, certain letters may be confused with each other when scripted.</li> <li>• Are the lengths of the names dissimilar* when scripted? *FDA considers the length of names different if the names differ by two or more letters.</li> <li>• Considering variations in scripting of some letters (such as <i>z</i> and <i>f</i>), is there a different number or placement of upstroke/downstroke letters present in the names?</li> <li>• Is there different number or placement of cross-stroke or dotted letters present in the names?</li> <li>• Do the infixes of the name appear dissimilar when scripted?</li> <li>• Do the suffixes of the names appear dissimilar when scripted?</li> </ul>	<p>Phonetic Checklist (Y/N to each question)</p> <ul style="list-style-type: none"> <li>• Do the names have different number of syllables?</li> <li>• Do the names have different syllabic stresses?</li> <li>• Do the syllables have different phonologic processes, such as vowel reduction, assimilation, or deletion?</li> <li>• Across a range of dialects, are the names consistently pronounced differently?</li> </ul>
--	--	--

**Table 5: Low Similarity Name Pair Checklist (i.e., combined score is  $\leq 54\%$ ).**

In most circumstances, these names are viewed as sufficiently different to minimize confusion. Exceptions to this would occur in circumstances where, for example, there are data that suggest a name with low similarity is nonetheless misinterpreted as a marketed product name in a prescription simulation study. In such instances, FDA would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

**Appendix B:** Prescription Simulation Samples and Results

**Figure 1. Mvasi Study (Conducted on December 23, 2016)**

Handwritten Medication Order/Prescription	Verbal Prescription
<p>Medication Order:</p> 	<p>Mvasi 500 mg Bring to clinic</p>
<p>Outpatient Prescription:</p> 	

**FDA Prescription Simulation Responses (Aggregate 1 Rx Studies Report)**

**Study Name: Mvasi**

As of Date 1/6/2017

306 People Received  
Study

98 People Responded

Study Name: Mvasi

Total	38	31	29	
INTERPRETATION	OUTPATIENT	VOICE	INPATIENT	TOTAL
ABVASI	0	1	0	1
AMVASI	0	2	0	2
AMVASSI	0	1	0	1
AMVASY	0	1	0	1
EMBAZE	0	1	0	1
EMVASEE	0	1	0	1

EMVASI	0	3	0	3
EMVASSI	0	1	0	1
EMVOSSI	0	1	0	1
HEADVOSSI	0	1	0	1
HEBVASI	0	1	0	1
HEMVACI	0	1	0	1
HEMVASE	0	1	0	1
HEMVASEE	0	1	0	1
HEMVASI	0	6	0	6
HEMVASSEY	0	1	0	1
HEMVASSI	0	1	0	1
HEMVOSSI	0	1	0	1
HENVASSEE	0	1	0	1
HEPVACI	0	1	0	1
HEPVACY	0	1	0	1
HEPVASEY	0	1	0	1
HEVAZI	0	1	0	1
INVASI	0	0	1	1
MIASI	3	0	3	6
MIRASI	1	0	3	4
MIVASI	1	0	2	3
MOASI	0	0	1	1
MORSI	0	0	1	1
MRASI	1	0	0	1
MUASI	6	0	1	7
MVASI	26	0	15	41
MVUSI	0	0	1	1
NIVASI	0	0	1	1

**Appendix C:** Highly Similar Names (e.g., combined POCA score is  $\geq 70\%$ )

No.	<b>Proposed name:</b> Mvasi <b>Proposed nonproprietary name:</b> bevacizumab-____ <b>Dosage form:</b> Injection <b>Strength(s):</b> 100 mg/4 mL and 400 mg/16 mL <b>Usual Dose:</b> 5 mg/kg to 15 mg/kg intravenous injection every 2 to 3 weeks, depending on indication.	<b>POCA Score (%)</b>	<b>Orthographic and/or phonetic differences in the names sufficient to prevent confusion</b>  <b>Other prevention of failure mode expected to minimize the risk of confusion between these two names.</b>
1.	Mvasi ***	100	Subject of this review.

**Appendix D:** Moderately Similar Names (e.g., combined POCA score is  $\geq 55\%$  to  $\leq 69\%$ ) with no overlap or numerical similarity in Strength and/or Dose

No.	Name	POCA Score (%)
1.	Masanti	60
2.	Mavik	62
3.	M-R-Vax II	60
4.	(b) (4) ***	60

**Appendix E:** Moderately Similar Names (e.g., combined POCA score is  $\geq 55\%$  to  $\leq 69\%$ ) with overlap or numerical similarity in Strength and/or Dose

	<p><b>Proposed name:</b> Mvasi  <b>Proposed nonproprietary name:</b> bevacizumab-____  <b>Dosage form:</b> Injection  <b>Strength(s):</b> 100 mg/4 mL and 400 mg/16 mL  <b>Usual Dose:</b> 5 mg/kg to 15 mg/kg intravenous injection every 2 to 3 weeks, depending on indication.</p>	<p><b>POCA Score (%)</b></p>	<p><b>Prevention of Failure Mode</b></p> <p><b>In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names</b></p>
1.	Amvaz	66	<p>The prefixes and suffixes of this name pair have sufficient orthographic differences. “Am” vs. “Mv” looks different when scripted. Amvaz may contain a down stroke letter “z” in the 5<sup>th</sup> position when written in cursive, which gives the name a different shape when compared to Mvasi***.</p> <p>The third syllables of this name pair sound different. The name Mvasi*** contains an extra syllable.</p> <p>Amvaz (amlodipine maleate) is a discontinued brand product (NDA 021435) with no generic equivalents available. NDA 021435 is in withdrawn FR effective status since July 8, 2011.</p> <p>Search of Drugs@FDA, Facts &amp; Comparisons and Red Book did not identify any Amlodipine maleate products.</p> <p>(Norvasc and generic amlodipine besylate are marketed.)</p>
2.	Amvisc	62	<p>The prefixes of this name pair have sufficient orthographic differences. “Am” vs. “Mv” looks different when scripted.</p> <p>The third syllables of this name pair sound different. The name Mvasi*** contains an extra syllable.</p>
3.	Avastin	52	<p>The prefixes and suffixes of this name pair have sufficient orthographic differences.</p> <p>The first and third syllables of this name pair sound different.</p>

	<p><b>Proposed name:</b> Mvasi</p> <p><b>Proposed nonproprietary name:</b> bevacizumab-_____</p> <p><b>Dosage form:</b> Injection</p> <p><b>Strength(s):</b> 100 mg/4 mL and 400 mg/16 mL</p> <p><b>Usual Dose:</b> 5 mg/kg to 15 mg/kg intravenous injection every 2 to 3 weeks, depending on indication.</p>	<p><b>POCA Score (%)</b></p>	<p><b>Prevention of Failure Mode</b></p> <p><b>In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names</b></p>
4.	(b) (4) ***	58	(b) (4)
5.	M.V.I.-12	62	<p>The infixes and suffixes of this name pair have sufficient orthographic differences.</p> <p>The third syllables of this name pair sound different.</p> <p>The name M.V.I.-12 contains an extra syllable.</p>
6.	Mirvaso	64	<p>The infixes of this name pair have sufficient orthographic differences.</p> <p>The first and third syllables of this name pair sound different.</p> <p>It is not likely that Mirvaso and Mvasi will be confused as the dosing and administration of these products are different. Mirvaso is a topical preparation for the once-daily treatment of facial erythema and rosacea. Mvasi is administered once every 2 to 3 weeks by intravenous infusion.</p>
7.	MVI	62	<p>The infixes and suffixes of this name pair have sufficient orthographic differences.</p> <p>The third syllables of this name pair sound different.</p>

	<p><b>Proposed name:</b> Mvasi</p> <p><b>Proposed nonproprietary name:</b> bevacizumab-_____</p> <p><b>Dosage form:</b> Injection</p> <p><b>Strength(s):</b> 100 mg/4 mL and 400 mg/16 mL</p> <p><b>Usual Dose:</b> 5 mg/kg to 15 mg/kg intravenous injection every 2 to 3 weeks, depending on indication.</p>	<p><b>POCA Score (%)</b></p>	<p><b>Prevention of Failure Mode</b></p> <p><b>In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names</b></p>
8.	Mytesi	57	<p>The infixes of this name pair have sufficient orthographic differences.</p> <p>The first and second syllables of this name pair sound different.</p> <p>It is not likely that Mytesi and Mvasi*** will be confused as the dosing and administration of these products are different. Mytesi is an oral tablet administered twice daily for the treatment of anti-retroviral induced, non-infective diarrhea. Mvasi** is administered once every 2 to 3 weeks by intravenous infusion.</p>
9.	Simvastatin	48	<p>The prefixes and suffixes of this name pair have sufficient orthographic differences. The length of the names (5 letters vs. 11 letters) also provides orthographic difference.</p> <p>The first and third syllables of this name pair sound different. The name Simvastatin contains an extra syllable.</p>
10.	Vansil	58	<p>The prefixes, infixes, and suffixes of this name pair have sufficient orthographic differences.</p> <p>The first, second, and third syllables of this name pair sound different. The name Mvasi contains an extra syllable.</p>

**Appendix F:** Low Similarity Names (e.g., combined POCA score is  $\leq 54$  %)

No.	Name	POCA Score (%)
1.	ALOXI	32
2.	ENVARUSUS	46
3.	M-CAPS	52
4.	MENVEO	34
5.	MI-ACID	53
6.	MOVANTIK	53
7.	MYCI	50
8.	MYRBETRIQ	35
9.	OVASITOL	42
10.	QVAR	38

**Appendix G:** Names not likely to be confused or not used in usual practice settings for the reasons described.

No.	Name	POCA Score (%)	Failure preventions
1.	(b) (4)***	67	Name identified in Name Entered by Safety Evaluator database. Unable to find product characteristics in commonly used internal databases.
2.	Maki	52	Name identified in RxNorm database. Unable to find product characteristics in commonly used internal databases.

**Appendix H:** Names not likely to be confused due to notable spelling, orthographic and phonetic differences.

No.	Name	POCA Score (%)
1.	Amgiva	56
2.	Basis	58
3.	Fiv-Asa	60
4.	Nasin	58
5.	Nava-Sc	56
6.	Nuessa	56
7.	Vasad	59

**Appendix I:** Names identified in the eDRLS database not likely to be confused due to notable spelling, orthographic and phonetic differences.

No.	Name
1.	N/A

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JANINE A STEWART  
02/08/2017

CHI-MING TU  
02/08/2017